Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Psyrri, A; Fayette, J; Harrington, K; Gillison, M; Ahn, MJ; Takahashi, S; Weiss, J; Machiels, JP; Baxi, S; Vasilyev, A; Karpenko, A; Dvorkin, M; Hsieh, CY; Thungappa, SC; Segura, PP; Vynnychenko, I; Haddad, R; Kasper, S; Mauz, PS; Baker, V; He, P; Evans, B; Wildsmith, S; Olsson, RF; Yovine, A; Kurland, JF; Morsli, N; Seiwert, TY
Seiwert, TY (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA.;Psyrri, A (通讯作者)，Natl Kapodistrian Univ Athens NKUA, Attikon Univ Hosp, Athens, Greece.;Seiwert, TY (通讯作者)，Johns Hopkins Univ, Baltimore, MD 21218 USA.
ANNALS OF ONCOLOGY, 2023; 34 (3): 262
